Andromed to float in Canada
This article was originally published in Clinica
Executive Summary
Andromed plans to raise C$7 million ($4.5 million) in financing, which includes a C$5 million IPO on the Montreal Stock Exchange. The company, which is developing non-invasive diagnostics and telemonitoring, will use the funds for R&D and marketing. The offering is expected to close on or around March 26.